{"nctId":"NCT04209634","briefTitle":"Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)","startDateStruct":{"date":"2020-01-27","type":"ACTUAL"},"conditions":["CD55-deficient Protein-losing Enteropathy","CHAPLE"],"count":10,"armGroups":[{"label":"Active PLE","type":"EXPERIMENTAL","interventionNames":["Drug: Pozelimab"]}],"interventions":[{"name":"Pozelimab","otherNames":["REGN3918"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Clinical diagnosis of CD55-deficient PLE/CHAPLE disease (based on a history of PLE), confirmed by biallelic CD55 loss-of-function mutation detected by genotype analysis\n* Active disease as defined by the protocol or inactive disease on eculizumab therapy (and whose treating physician has the expectation of future access to renewed eculizumab treatment should this be required), and is willing to discontinue eculizumab during screening and start pozelimab at baseline with no eculizumab wash-out\n\nKey Exclusion Criteria:\n\n* History of meningococcal infection\n* No documented meningococcal vaccination within 3 years prior to screening and patient unwilling to undergo vaccination during the study\n* No documented vaccination for Haemophilus influenzae and Streptococcus pneumoniae if applicable based on local practice or guidelines prior to screening and patient unwilling to undergo vaccination during the study if required per local practice or guidelines\n* Presence of a concomitant disease that leads to hypoproteinemia at the time of starting pozelimab\n* A concomitant disease that leads to secondary intestinal lymphangiectasia such as a fontan procedure for congenital heart disease\n\nNote: Other protocol-defined Inclusion/Exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Active Disease at Baseline Who Achieved Normalization of Serum Albumin and Improvement in Prespecified Clinical Outcomes at Week 24","description":"Normalization of serum albumin was defined as serum albumin within the normal range at least 70 percent (%) of measurements between weeks 12 and 24, and no single albumin measurement of \\<2.5 grams per deciliter (g/dL) between weeks 12 and 24, and no requirement for albumin infusion between weeks 12 and 24. Improvement in the following 4 prespecified clinical outcomes that were evaluable for improvement at baseline, without worsening of the others: Daily bowel movement frequency, the presence and severity of facial edema (physician-reported), the presence and severity of peripheral edema (physician-reported), and the participant/caregiver assessment of frequency of problematic abdominal pain. Percentage of participants with active disease at baseline who achieved normalization of serum albumin and improvement in prespecified clinical outcomes at Week 24 were reported.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs","description":"TEAEs are defined as AEs that developed or worsened during the on-treatment period. The on-treatment period is defined as the time from first dose of investigational product up to 21 weeks after the last dose of investigational product. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the patient's normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Most Bothersome Signs and Symptoms at Week 24","description":"Improvement in most bothersome sign/symptom determined using semi-structured concept elicitation interview, from 'core' clinical endpoints of frequency of bowel movements, peripheral edema, facial edema, abdominal pain frequency, nausea, vomiting, stool consistency.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bowel Movements Per Day Based on a 1-week Average up to Week 24","description":"Daily bowel movements captured by e-diary. The number of bowel movements per day was calculated each week of the study. It was based on a 1-week average and calculated as the sum of the number of bowel movements in a given week divided by the number of days with non-missing bowel movement frequency data. If more than 3 days of bowel movement data was missing in a given week, bowel movement frequency data was considered missing for that week.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Per Week With >=1 Bowel Movement of Loose/Watery Stool Consistency at Week 24","description":"The number of days per week with \\>=1 loose/watery bowel movement, is calculated each week of the study as the sum of the number of days with \\>=1 loose/watery bowel movement in a given week divided by the number of days with non-missing stool consistency data and then multiplied by 7, is presented. If more than 3 days of stool consistency data was missing in a given week, stool consistency data was considered missing for that week.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abdominal Ascites at Week 24","description":"The measurement of abdominal ascites (excess abdominal fluid) was based on abdominal circumference. Abdominal circumference was measured regardless of the physician's assessment of the presence or absence of ascites.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Value of Albumin at Specified Timepoints up to Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of albumin. Absolute value of albumin at specified timepoints was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.160","spread":"0.5296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.267","spread":"0.4000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.311","spread":"0.4485"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.589","spread":"0.4428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.025","spread":"0.3955"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.167","spread":"0.3841"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.411","spread":"0.7026"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.188","spread":"0.3137"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.322","spread":"0.2279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.288","spread":"0.2748"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.363","spread":"0.2615"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.367","spread":"0.3674"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.344","spread":"0.2555"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.449","spread":"0.2539"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.422","spread":"0.2906"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.544","spread":"0.2603"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Protein, and Immunoglobulin G (IgG) at Baseline and Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of protein and IgG. Absolutes values of protein and IgG measured as g/L at baseline and Week 24 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.50","spread":"6.996"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.22","spread":"4.969"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.183","spread":"0.9103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.301","spread":"2.0503"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Immunoglobulin (Ig), Immunoglobulin M (IgM), and Immunoglobulin A (IgA) at Baseline and Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of Ig, IgM and IgA. Absolute value of Ig, IgM and IgA measured as mg/dL at baseline and Week 24 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"318.2","spread":"113.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1430.1","spread":"263.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":"28.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180.3","spread":"74.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","spread":"18.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.8","spread":"52.46"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Vitamin B12 at Baseline and Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of vitamin B12. Absolute values of vitamin B12 at baseline and Week 24 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158.5","spread":"52.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"383.1","spread":"102.73"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Iron and Unsaturated Iron Binding Capacity at Baseline and Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of unsaturated iron and unsaturated iron binding capacity measured as micromoles per liter (mcmol/L) at baseline and Week 24 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"1.478"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.38","spread":"5.036"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.24","spread":"12.357"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.95","spread":"12.049"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Vitamin B9 up to Week 24","description":"Absolute Values of Vitamin B9 - Central Lab","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.80","spread":"15.017"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.07","spread":"14.342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.32","spread":"8.042"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.89","spread":"9.646"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.01","spread":"10.610"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.91","spread":"15.436"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.93","spread":"6.538"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Ferritin at Baseline and Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of iron indices. Absolute values of ferritin was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"5.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":"7.86"}]}]}]},{"type":"SECONDARY","title":"Absolute Values of Magnesium, Total Cholesterol, and Triglycerides at Week 24","description":"Blood samples were collected from participants at defined time points for the assessment of magnesium, total cholesterol, and triglycerides. Absolute values of magnesium, total cholesterol, and triglycerides measured as mmol/L at baseline and Week 24 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.793","spread":"0.0381"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.858","spread":"0.0245"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.819","spread":"0.8786"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.604","spread":"0.3118"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.033","spread":"0.7946"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.094","spread":"0.3745"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Alpha-1 Antitrypsin Levels in Stool at Week 12 and Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-527.80","spread":"318.818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-463.71","spread":"204.250"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Alpha-1 Antitrypsin Levels in Blood at Week 12 and Week 24","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.8","spread":"33.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.4","spread":"35.89"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Active Disease at Baseline Who Maintained Disease Control","description":"Measured by normalization of serum albumin, no worsening of facial or peripheral edema, increase in bowel movement, or increase in abdominal pain frequency, no increase in dose of permitted concomitant medication for the treatment of PLE at any time as described in the protocol","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physician Assessment of Facial Edema Based on a 5-point Likert Rating Scale","description":"The physician assessment of facial edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physician Assessment of Peripheral Edema Based on a 5-point Likert Rating Scale","description":"The physician assessment of peripheral edema is based on a 5-point Likert scale ranging from no edema (1) to very severe edema (5).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Food and Drink Limitations as Assessed by the PedsQL™ GI Symptom Scales' Food and Drink Limits Sub-scale","description":"Frequency of limitations is assessed on a 5-point Likert response scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse scored and linearly transformed to a 0 to 100 scale, where lower scores indicate more frequent problems with food and drink limitations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.40","spread":"36.653"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the PedsQL™ Generic Core Scales","description":"Physical functioning, emotional functioning, social functioning, and school/work/studies functioning is assessed using a 5-point Likert scale, ranging from never a problem (0) to almost always a problem (4). Items were reverse-scored and linearly transformed to a 0 to 100 scale, with higher scores indicating better HRQoL. The total scale score is computed as the sum of all the items over the number of items answered on individual scales. Subscale score is calculated as the sum of the items in the scale divided by the number of items answered in the scale.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.55","spread":"17.023"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.45","spread":"39.900"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":"28.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"20.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.43","spread":"19.518"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Albumin Infusion by 24 Week Periods","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Albumin Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.400","spread":"0.6103"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Albumin Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127.489","spread":"81.0666"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Albumin Values","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Protein Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.13","spread":"10.789"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Total Protein","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Immunoglobulin (Ig) Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1271.2","spread":"261.91"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Ig Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IgG Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.626","spread":"2.2486"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for IgG Values","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IgM Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.0","spread":"51.21"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for IgM Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IgA Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":"28.78"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for IgA Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Vitamin B12 Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.8","spread":"56.07"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Vitamin B12 Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Vitamin B9 (Folate) Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.92","spread":"10.241"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Vitamin B9 (Folate) Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Iron Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.82","spread":"4.091"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Iron Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Unsaturated Iron Binding Capacity","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.20","spread":"13.811"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Unsaturated Iron Binding Capacity","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ferritin Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":"23.67"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Ferritin Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Magnesium Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.0606"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Magnesium Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Cholesterol Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.072","spread":"0.7299"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Fasting Cholesterol Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Triglycerides Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.710","spread":"0.9086"}]}]}]},{"type":"SECONDARY","title":"Time to First Normalization for Fasting Triglycerides Values","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Used Concomitant Medication","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hospitalization Days by 24 Week Period","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight Z-Score","description":"Weight-for-age z-score compares a participant's weight to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Body weight z-score, regardless of magnitude, represents catch-up growth.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.924","spread":"0.7529"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Height Z-Score","description":"Height-for-age z-score compares a participant's height to children of the same age and sex from a healthy reference population. A z-score reflects an individual score as compared to a population mean and is expressed in units of standard deviation above (positive values) and below (negative values). Any increase in height z-score, regardless of magnitude, represents catch-up growth.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.079","spread":"0.6469"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Complement Activity Complement Hemolytic Assay (CH50)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-241.6","spread":"39.79"}]}]}]},{"type":"SECONDARY","title":"Concentrations of Total Pozelimab in Serum","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":"68.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":"103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":"110"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":"106"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"306","spread":"111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":"115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":"141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":"136"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"421","spread":"129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"467","spread":"127"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"517","spread":"142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"492","spread":"131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"461","spread":"115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"430","spread":"134"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"410","spread":"104"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Pozelimab","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":10},"commonTop":["Abdominal pain","Vomiting","Nasopharyngitis","Upper respiratory tract infection","Rhinitis"]}}}